Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. Unlike 1,4-benzodiazepines, it has a flatter structure that is associated with a more favorable profile regarding sedation and cognitive impairment. It undergoes extensive hepatic metabolism via CYP3A4, CYP2C19, and CYP2B6.
## Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years. Off-label use includes treatment-resistant focal or generalized epilepsy and acute anxiety.
## Adult Dosing
* **Initial Dose:** 10 mg/day.
* **Titration:** Increase to target dose of 20 mg/day after 1 week as tolerated.
* **Maximum Dose:** 40 mg/day (divided BID).
## Pediatric Dosing (≥2 years)
Weight-based dosing approach:
* **≤30 kg:** Initial 5 mg/day. May increase after 1 week to a maximum of 20 mg/day (divided BID).
* **>30 kg:** Initial 10 mg/day. May increase after 1 week to a maximum of 40 mg/day (divided BID).
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50% in patients with mild to moderate impairment (Child-Pugh A or B). Avoid in severe impairment.
* **Renal Impairment:** No specific adjustment required; use caution in severe renal failure.
* **CYP2C19 Poor Metabolizers:** Reduce starting dose or escalate more slowly; clobazam levels can increase up to 5-fold.
## Contraindications
* Known hypersensitivity to clobazam or its components.
* History of severe allergic reaction to benzodiazepines.
## Adverse Effects
* **Common:** Somnolence, lethargy, sedation, drooling (sialorrhea), pyrexia, constipation, and vomiting.
* **Severe:** Respiratory depression, sedation (additive with other CNS depressants), physical dependence/withdrawal with abrupt cessation, and risk of severe skin reactions (SJS/TEN).
## Key Drug Interactions
* **CYP2C19 Inhibitors:** (e.g., fluconazole, fluvoxamine, omeprazole) Significantly increase plasma concentrations of the active metabolite, N-desmethylclobazam.
* **CNS Depressants:** Alcohol, opioids, and other sedative-hypnotics increase the risk of profound sedation and respiratory depression.
* **Hormonal Contraceptives:** May reduce the efficacy of estrogen-containing oral contraceptives.
* **Valproic Acid:** May increase plasma levels of N-desmethylclobazam.
## Monitoring
* **Clinical:** Monitor for excessive sedation, respiratory status, and changes in seizure frequency/pattern.
* **Behavioral:** Assess for mood changes, emergence of suicidal ideation, or worsening depression.
* **Dermatologic:** Monitor for rash, blistering, or mucosal lesions (immediate medical attention required).
## Clinical Pearls
* **Withdrawal:** Abrupt discontinuation can precipitate status epilepticus; taper gradually over several weeks.
* **Administration:** Tablets can be swallowed whole or crushed; oral suspension must be shaken well before each use.
* **Tolerance:** Clinical studies suggest that efficacy in seizure reduction may decrease over time in some patients due to the development of tolerance.
* **Controlled Substance:** Schedule IV medication with potential for abuse and dependence.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practices may vary by institution. Always verify dosages, contraindications, and drug interactions against current, peer-reviewed clinical guidelines and official prescribing information (package insert) before prescribing or administering medication.
